Adverse reactions of Lenvatinib

In DTC, the most common adverse reactions (incidence ≥30%) for lenvatinib are hypertension, fatigue, diarrhea, arthralgia/myalgia,  decreased appetite, decreased weight, nausea, stomatitis, headache,  vomiting, proteinuria, palmar-plantar erythrodysesthesia syndrome,  abdominal pain, and dysphonia.

In RCC:

The most common adverse reactions (incidence ≥20%) for lenvatinib and pembrolizumab are fatigue, diarrhea, musculoskeletal  pain, hypothyroidism, hypertension, stomatitis, decreased appetite, rash,  nausea, decreased weight, dysphonia, proteinuria, palmar-plantar  erythrodysesthesia syndrome, abdominal pain, hemorrhagic events,  vomiting, constipation, hepatotoxicity, headache, and acute kidney  injury.

The most common adverse reactions (incidence ≥30%) for lenvatinib and everolimus are diarrhea, fatigue, arthralgia/myalgia, decreased appetite, vomiting, nausea, stomatitis/oral inflammation, hypertension, peripheral edema, cough, abdominal pain, dyspnea, rash, decreased weight, hemorrhagic events, and proteinuria.

In HCC, the most common adverse reactions (incidence ≥20%) for lenvatinib are hypertension, fatigue, diarrhea, decreased appetite,  arthralgia/myalgia, decreased weight, abdominal pain, palmar-plantar  erythrodysesthesia syndrome, proteinuria, dysphonia, hemorrhagic events,  hypothyroidism, and nausea.

In EC, the most common adverse reactions (incidence ≥20%) for lenvatinib and pembrolizumab are hypothyroidism, hypertension, fatigue,  diarrhea, musculoskeletal disorders, nausea, decreased appetite, vomiting, stomatitis, decreased weight, abdominal pain, urinary tract infection,  proteinuria, constipation, headache, hemorrhagic events, palmar-plantar  erythrodysesthesia, dysphonia, and rash.

from FDA，2024.06